News ImmuneRegen NewsImmuneRegen Achieves Key Milestone in Testing of Potential Infectious Disease TreatmentCompany Ships Viprovex(TM) for Study Sponsored by Singapore's DSO National Laboratories January 16, 2007 7:00 AM ET SCOTTSDALE, Ariz., Jan. 16 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), announced today that it has completed the initial shipment of its proprietary compound Viprovex(TM) to Singapore's Defense Medical & Environmental Research Institute, DSO National Laboratories ("DSO"), for use in a Pilot Study on Acute Melioidosis. Also called Whitmore's disease, melioidosis is an infectious disease caused by the bacterium Burkholderia pseudomallei, and is endemic to Southeast Asia. The study to investigate the therapeutic effects of Viprovex(TM) on acute melioidosis is funded by DSO and is expected to be completed during the third quarter of this year. Melioidosis is quite common in Southeast Asia, with the greatest concentration of cases reported in Vietnam, Cambodia, Laos, Thailand, Malaysia, Myanmar (Burma), and northern Australia. Additionally, it is seen in the South Pacific, Africa, India, and the Middle East. The causative agent, Burkholderia pseudomallei along with the related Burkholderia mallei, the causative agent of glanders, can be transmitted from animals to man as well as from person to person. The bacteria can be found in contaminated water and soil and is spread to humans and animals through direct contact with the contaminated source. Mortality rate for melioidosis varies and is as high as 90% particularly when the bacteria is aerosolized. The Centers for Disease Control and Prevention (CDC) considers both as potential agents for biological warfare and biological terrorism and there is currently no vaccine for either melioidosis or glanders. "We are pleased that a prestigious entity such as the DSO has selected our compound to test against this highly infectious disease," said ImmuneRegen's CEO Michael Wilhelm. "We recognize that melioidosis currently represents a significant health threat on the Asian continent, as reflected by the high mortality rates associated with the disease and has the potential to be used as an agent by terrorist organizations." These studies augment the ongoing research being conducted by ImmuneRegen on so-called "Threats of the 21st Century" which include radioactive contamination, anthrax, pandemic influenza and chemical contamination, areas in which ImmuneRegen's Radilex and Viprovex hold promise of possible effectiveness in ameliorating morbidity and mortality in small animal studies. About Radilex(TM) and Viprovex(TM) About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|